{
  "author": "PDWAMMO",
  "the_new_excerpt": "I AM NOT A FINANCIAL ADVISOR\n\n$TXMD - TherapeuticsMD, Inc. is an innovative, leading healthcare company,\nfocused on developing and commercializing novel products exclusively for women.\nTheir products are designed to address the unique changes and challenges women\nexperience through the various…",
  "original_created_utc": 1613444563,
  "localize": [
    {
      "locale": "zh",
      "the_new_excerpt": "我不是财务顾问\n\n$TXMD - TherapeuticsMD公司是一家创新的、领先的医疗保健公司。\n专注于开发和商业化女性专用的新型产品。\n他们的产品旨在解决女性的独特变化和挑战。\n经验，通过各种...",
      "title": "大家好，这里是$TXMD的一些DD。"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "我不是財務顧問\n\n$TXMD - TherapeuticsMD公司是一家創新的、領先的醫療保健公司。\n專注於開發和商業化女性專用的新型產品。\n他們的產品旨在解決女性的獨特變化和挑戰。\n經驗，通過各種...",
      "title": "大家好，這裏是$TXMD的一些DD。"
    }
  ],
  "title": "Hey all, here is some DD on $TXMD",
  "created_utc": 1613482884,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>I AM NOT A FINANCIAL ADVISOR</p>\n\n<p><strong>$TXMD</strong> - TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Their products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues.</p>\n\n<p>- On Feb. 11 they announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TXMD. The offering is expected to close on February 16 (tomorrow). In addition, TXMD has granted the underwriter a 30-day option to purchase up to approximately 8.9 million additional shares of common stock.</p>\n\n<p>- Drug pipeline below:</p>\n\n<ol>\n<li>TXMD announces the submission of a New Drug Application for TX-001HR (Bijuva- a pill for the treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause) in December.</li>\n<li>Bijuva - The first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women.</li>\n<li>Segesterone Acetate - The first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection from pregnancy.</li>\n<li>Yuvvexy - an applicator-free, vaginal, estradiol softgel capsule being proposed for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.</li>\n</ol>\n\n<p>- Market Watch rates this stock as a buy, with a high stock price at $10, a median of $7, and a low of $3. It&#39;s current price is $1.92</p>\n</div><!-- SC_ON -->",
  "score": 78,
  "permalink": "/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/",
  "subreddit": "investing",
  "id": "lku7ah",
  "is_self": true,
  "media": null,
  "is_video": false,
  "source_updated_at": 1613728621154
}